Acute Myocardial Infarction Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – Estimates DelveInsight | Eli Lilly, Idorsia, AstraZeneca, Janssen, BMS, Amgen, CSL

February 12 16:24 2024
Acute Myocardial Infarction Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) -  Estimates DelveInsight | Eli Lilly, Idorsia, AstraZeneca, Janssen, BMS, Amgen, CSL
As per DelveInsight, the Acute Myocardial Infarction Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Acute Myocardial Infarction, advancements in diagnostics, and the launch of new therapies in the market. Emerging therapies and a focus on preventive cardiology are immensely reshaping patient care approaches. Ongoing research in personalized medicine holds promise for further market transformation and treatment outlook.

DelveInsight’s “Acute Myocardial Infarction Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Myocardial Infarction market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Acute Myocardial Infarction drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Myocardial Infarction treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Acute Myocardial Infarction: An Overview

Acute Myocardial Infarction (AMI) is myocardial necrosis resulting from acute obstruction of a coronary artery. Acute MI, along with unstable angina, is considered an acute coronary syndrome. Acute MI includes both non-ST-segment-elevation Myocardial Infarction (NSTEMI) and ST-segment-elevation Myocardial Infarction (STEMI).

Symptoms associated with acute Myocardial Infarction include chest pain, which may appear as a sensation of tightness or pressure initially. Pain often radiates to the left arm but may also radiate to the lower jaw, neck, right arm, back, and upper abdomen. Chest pain may accompany sweating, nausea or vomiting, and fainting.

Cardiac troponin I (cTnI) and troponin T (cTnT) are components of the contractile apparatus of myocardial cells and are expressed almost exclusively in the heart; these are used as MI predictors. The increasing use of cardiac biomarkers for diagnosing MI during the past two decades and the changing cutoff levels for the laboratory tests used to define myocardial injury or MI are the most apparent complicating factors in many studies of MI trends.

Diagnosis is based on typical clinical features, ECG findings, and elevation of cardiac biomarkers. Definitive diagnosis requires cardiac catheterization, which serves both diagnostic and therapeutic purposes. All patients suspected of having ACS should be considered for emergency re-vascularization; additional aspects of treatment include anticoagulation, antiplatelet therapy, statin therapy, and other adjunctive measures. Secondary prevention consists of dual antiplatelet therapy, the initiation of beta-blocker and/or ACE inhibitors, statin therapy, and addressing any modifiable risk factors.

Cardiac markers (serum markers of myocardial cell injury) are cardiac enzymes (eg, creatine kinase-MB isoenzyme [CK-MB]) and cell contents (e.g., troponin I, troponin T, myoglobin) that are released into the bloodstream after myocardial cell necrosis. The markers appear at different times after injury, and levels decrease at different rates. Sensitivity and specificity for myocardial cell injury vary significantly among these markers, but the troponins (cTn) are the most sensitive and specific and are the markers of choice.

Acute Myocardial Infarction Market Key Facts

  • According to Benjamin et al. (2019), the estimated annual incidence of Myocardial Infarction is 605,000 new attacks and 200,000 recurrent attacks. The average age at first MI is 65.5 years for males and 72 years for females. The incidence rate of AMI is 0.3% in the US.
  • According to Inserm (2019), France has an average of 80,000 Myocardial Infarction annually. Women are four times less likely to have a heart attack than men before menopause. However, the cases among women are increasing due to factors like smoking and obesity. Post-menopause, the risks are equivalent for both sexes.
  • Among the 7MM, the highest number of incident cases were observed in the US, which is around 830,000 in 2023.
  • Among EU4 and the UK, Germany accounted for the highest number of incident cases, followed by Italy in 2023. 
  • As per the Japanese Circulation Society database, there were around 75,700 cases of AMI in Japan in 2019.

Acute Myocardial Infarction Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Myocardial Infarction pipeline therapies. It also thoroughly assesses the Acute Myocardial Infarction market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Acute Myocardial Infarction drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Acute Myocardial Infarction Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Acute Myocardial Infarction epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Acute Myocardial Infarction epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Acute Myocardial Infarction Epidemiology, Segmented as –

  • Type-specific Incidence of AMI in the 7MM
  • Total Incident Cases of AMI in the 7MM
  • Gender-specific Incidence of AMI in the 7MM

Acute Myocardial Infarction Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Myocardial Infarction market or expected to be launched during the study period. The analysis covers the Acute Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Acute Myocardial Infarction drugs based on their sale and market share.

The report also covers the Acute Myocardial Infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Acute Myocardial Infarction companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Acute Myocardial Infarction Market Will Evolve and Grow by 2032:

Acute Myocardial Infarction Therapeutics Analysis

The goals of initial treatment of an AMI are relief of pain, immediate identification of ST changes via 12-lead EKG, initiation of reperfusion (if the patient is a candidate), and assessment and treatment of hemodynamic abnormalities. Pain relief is best achieved with oxygen, nitroglycerin, and morphine sulfate. Patients with ST-segment elevation or a new LBBB with 12 h or fewer symptoms are candidates for reperfusion therapy. 

Further treatment of an MI may be separated into two pathways depending on whether or not the patient has a STEMI or an NSTEMI. The pharmacologic treatment of MI can be further broken down into several medications that improve survival, decrease recurrent ischemic events, and provide symptomatic relief. The primary treatment is followed by a multimodal regimen of therapies. The treatment starts with rapid diagnostic tests and serial biomarker analysis to classify the disease.

The current market has been segmented into different commonly used therapeutic classes based on the prevailing treatment pattern across the 7MM, which presents minor variations in the overall prescription pattern. Antiplatelet agents, Anticoagulants, Vasodilators, Beta Blockers, Lipid-lowering drugs/Statins, ACE inhibitors, ARBs (Angiotensin-II receptor Blockers), and Calcium channel blockers are the major classes that have been covered in the forecast model.

Acute Myocardial Infarction Companies Actively Working in the Therapeutics Market Include

  • Boehringer Ingelheim
  • Eli Lilly and Company
  • Idorsia Pharmaceuticals
  • Recardio
  • Janssen Pharmaceutical
  • Bristol Myers Squibb
  • AstraZeneca
  • Faraday Pharmaceuticals
  • CSL Behring
  • Amgen

And others

Emerging and Marketed Acute Myocardial Infarction Therapies Covered in the Report Include:

  • TNKASE (tenecteplase): Genentech
  • ZONTIVITY (vorapaxar): Merck
  • REPATHA (evolocumab): Amgen
  • JARDIANCE: Boehringer Ingelheim/Eli Lilly and Company
  • Selatogrel: Idorsia Pharmaceuticals
  • Asundexian: Bayer

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies:

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Acute Myocardial Infarction Competitive Intelligence Analysis

4. Acute Myocardial Infarction Market Overview at a Glance

5. Acute Myocardial Infarction Disease Background and Overview

6. Acute Myocardial Infarction Patient Journey

7. Acute Myocardial Infarction Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Acute Myocardial Infarction Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Myocardial Infarction Unmet Needs

10. Key Endpoints of Acute Myocardial Infarction Treatment

11. Acute Myocardial Infarction Marketed Therapies

12. Acute Myocardial Infarction Emerging Drugs and Latest Therapeutic Advances

13. Acute Myocardial Infarction Seven Major Market Analysis

14. Attribute Analysis

15. Acute Myocardial Infarction Market Outlook (In US, EU5, and Japan)

16. Acute Myocardial Infarction Companies Active in the Market

17. Acute Myocardial Infarction Access and Reimbursement Overview

18. KOL Views on the Acute Myocardial Infarction Market

19. Acute Myocardial Infarction Market Drivers

20. Acute Myocardial Infarction Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Diffuse Large B-cell Lymphoma Market

“Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diffuse Large B-cell Lymphoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author